Life Sciences Partner Examines New Regulations that Impact China Drug and Medical Device Inspections
Life sciences partner Katherine Wang (Shanghai) examined new China regulations that impact drug and device inspection in an Asia Pacific Biotech News article published on Feb 11.
The regulations are designed to verify whether foreign drug and device companies’ research and manufacturing processes adhere to medical product standards in China. The regulations seek to verify authenticity, reliability and compliance of R&D and manufacturing activities.